subscribeSubscribe
NICE recommends all-oral treatment for multiple myeloma

NICE recommends all-oral treatment for multiple myeloma
EUROPEAN PHARMACEUTICAL REVIEW
19 Jan 2023
Share Share
Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod

Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
GLOBENEWSWIRE
07 Feb 2022
Share Share
Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)

Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)
BUSINESS WIRE
11 Sep 2020
Share Share
Takeda`s ixazomib comes up short in first-line multiple myeloma study

Takeda`s ixazomib comes up short in first-line multiple myeloma study
SEEKINGALPHA
09 Sep 2020
Share Share
MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis

MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
JIHO
26 Jun 2020
Share Share
Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™

Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™
PRESS RELEASE
12 Jun 2020
Share Share
Takeda`s Ninlaro combo fails to hit main goal

Takeda`s Ninlaro combo fails to hit main goal
PHARMAFILE
11 Mar 2020
Share Share
EMA and FDA historically agree on just about every new drug approval, but is that slowly changing?

EMA and FDA historically agree on just about every new drug approval, but is that slowly changing?
Zachary Brennan ENDPTS
20 Aug 2019
Share Share
EMA & FDA Historically Agree on Just About Every New Drug Approval

EMA & FDA Historically Agree on Just About Every New Drug Approval
Zachary Brennan RAPS
16 Aug 2019
Share Share
EMA & FDA Historically Agree on Just About Every New Drug Approval

EMA & FDA Historically Agree on Just About Every New Drug Approval
Zachary Brennan RAPS
16 Aug 2019
Share Share